Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Recent advances in the production of biomedical systems based on polyhydroxyalkanoates and exopolysaccharides

Full text
Author(s):
Carvalho, Layde T. [1] ; Vieira, Thiago A. [1] ; Zhao, Yanjun [2, 3] ; Celli, Annamaria [4] ; Medeiros, Simone F. [1, 5] ; Lacerda, Talita M. [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Engn Sch Lorena, Biotechnol Dept, BR-12602810 Lorena, SP - Brazil
[2] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 3W072 - Peoples R China
[3] Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 3W072 - Peoples R China
[4] Univ Bologna, Dept Civil Chem Environm & Mat Engn, Via Terracini 28, I-40131 Bologna - Italy
[5] Univ Sao Paulo, Engn Sch Lorena, Chem Engn Dept, BR-12602810 Lorena, SP - Brazil
Total Affiliations: 5
Document type: Review article
Source: International Journal of Biological Macromolecules; v. 183, p. 1514-1539, JUL 31 2021.
Web of Science Citations: 2
Abstract

In recent years, growing attention has been devoted to naturally occurring biological macromolecules and their ensuing application in agriculture, cosmetics, food and pharmaceutical industries. They inherently have antigenicity, low immunogenicity, excellent biocompatibility and cytocompatibility, which are ideal properties for the design of biomedical devices, especially for the controlled delivery of active ingredients in the most diverse contexts. Furthermore, these properties can be modulated by chemical modification via the incorporation of other (macro)molecules in a random or controlled way, aiming at improving their functionality for each specific application. Among the wide variety of natural polymers, microbial polyhydroxyalkanoates (PHAs) and exopolysaccharides (EPS) are often considered for the development of original biomaterials due to their unique physicochemical and biological features. Here, we aim to fullfil a gap on the present associated literature, bringing an up-to-date overview of ongoing research strategies that make use of PHAs (poly (3-hydroxybutyrate), poly (3-hydroxybutyrate-co-3-hydroxyvalerate), poly (3-hydroxyoctanoate), poly(3-hydroxypropionate), poly (3hydroxyhexanoate-co-3-hydroxyoctanoate), and poly (3-hydroxybutyrate-co-3-hydroxyhexanoate)) and EPS (bacterial cellulose, alginates, curdlan, pullulan, xanthan gum, dextran, hyaluronan, and schizophyllan) as sources of interesting and versatile biomaterials. For the first time, a monograph addressing the properties, pros and cons, status, challenges, and recent progresses regarding the application of these two important classes of biopolymers in biomedicine is presented. (c) 2021 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 19/04269-0 - Evaluation of novel polymer nanoparticles as potential carriers for simultaneous release of a photosensitising agent and an active chemotherapeutic agent
Grantee:Simone de Fátima Medeiros Sampaio
Support Opportunities: Regular Research Grants
FAPESP's process: 19/12940-4 - Biodegradable and biocompatible nanoparticles for controlled release of paclitaxel and fluorouracil for the treatment of Hepatocellular Carcinoma (HCC)
Grantee:Layde Teixeira de Carvalho
Support Opportunities: Scholarships in Brazil - Doctorate